LBL-058

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameLBL-058
Drug Alias NameLBL-058
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > T cell engagers
Mechanisms of ActionAnti-Delta-like protein 3Anti-CD3
TargetsDelta-like protein 3T cell surface glycoprotein CD3
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Leadsbiolabs Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Leadsbiolabs Co Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung CarcinomaCarcinoma, Neuroendocrine
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A